Skip to main content

Table 7 Economic impact of observed comorbidities (mean total cost) among the populations with one comorbidity. (average cost excluding the related HCV therapy costs)

From: Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

  HIV+
Mono-infected patients
N = 251
HIV/HCV
Co-infected patients
N = 200
Delta between HIV/HCV and HIV+ patients
[%]
p-value between HIV/HCV and HIV+ patients
Cardiovascular comorbidities € 10,116.58 € 20,724.95
€ 11,004.28*
51.19%
8.07%*
0.001
> 0.050*
Neurocognitive impairments € 7,706.43 € 11,641.29
€ 11,641.29*
33.80%
33.80%*
< 0.001
< 0.001*
HBV infection € 9,551.84 € 28,790.25
€ 13,230.36*
66.82%
27.80%*
> 0.050
> 0.050*
Bone events € 8,953.19 € 12,097.29
€ 10,972.37*
25.99%
18.40%*
> 0.050
> 0.050*
Renal impairments € 9,162.64 € 8038.49
€ 8038.49*
−13.98%
− 13.98%*
> 0.050
> 0.050*
Diabetes € 10,249.13 € 26,723.49
€ 11,541.70*
61.65%
10.99%*
> 0.050
> 0.050*
One-way ANOVA 0.215 0.017   
  1. *Average cost without considering costs incurred for HCV therapy